rs or administration sets at concentrations of 0.18 mg/mL to 0.33 mg/mL.
Stability
NIPENT vials are stable at refrigerated storage temperature 2° to 8°C (36° to 46°F) for the period stated on the package. Vials reconstituted or reconstituted and further diluted as directed may be stored at room temperature and ambient light but should be used within 8 hours because NIPENT contains no preservatives.
HOW SUPPLIED
NIPENT (pentostatin for injection) is supplied as a sterile lyophilized white to off-white powder in single-dose vials containing 10 mg of pentostatin. The vials are packed in individual cartons. NDC 62701-800-01
Storage: Store NIPENT vials under refrigerated storage conditions 2° to 8°C (36° to 46°F).
Rx Only
REFERENCES
Malspeis L, et al. Clinical Pharmacokinetics of 2'-Deoxycoformycin. Cancer Treatment Symposia 2:7-15, 1984.
Recommendations for the safe handling of parenteral antineoplastic drugs. NIH publication 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, NC 20402.
AMA council report. Guidelines for handling parenteral antineoplastics. JAMA 253:1590-2, 1985.
National Study Commission on Cytotoxic Exposure-Recommendations for handling cytotoxic agents. Available from Louis P. Jeffery, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Ave, Boston, Massachusetts 02115.
Clinical Oncology Society of Australia: Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia 1:426-8, 1983.
Jones RB, et al. Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. CA: A Cancer Journal for Clinicians 33:258-63, 1983.
American Society of Hospital Pharmacists technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033-49, 1990.
800P1 Rev. April, 1998
|
